23 September 2022
The Federal Antimonopoly Service (FAS) of the Russian Federation has approved prices for the first antitumor generic with INN eribulin. This was reported by the FAS press service.
“The agreed marginal prices for Eribulin-Promomed produced by AO Biokhimik are 27% lower than the prices for the foreign-made reference drug. This will make it more affordable for Russian citizens,” the report says.
The approved price of one vial of the domestic drug is 17,476 rubles, while the marginal cost of a similar vial of the reference drug is 23,794 rubles, the Federal Antimonopoly Service stressed.
The FAS previously approved the price of Convacel COVID vaccine.
PrintGrand finale from a veritable stalwart of neuroscience
09 November 2023
Battle of pharma advocates – in search of the ideal migraine therapy
09 November 2023
31 October 2023
Long COVID study expanded across Europe
30 November 2023
Ethical, Regulatory, and Operational Considerations for Cell and Gene Therapy Research in Children
30 November 2023
Prevention, Treatment for Migraine Rapidly Evolves, Calling for Development of Novel Drugs
29 November 2023
Imaging AI hogs the spotlight at RSNA, with debuts from GE, Siemens, Philips
29 November 2023